Nimotuzumab plus chemotherapy in the posterior-line treatment for lung adenocarcinoma with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors resistance.

Authors: Kaihua Lu, Meiling Zhang, Qian Wang, Ao Sun, Yan Xiang, Jingwen Liu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20636

Source: Full article

e20636